Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination - Test2 - elhamkhani - TriplyDB

Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination

Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination

http://www.wikidata.org/entity/Q34517948

about

Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs NKT cell-dependent glycolipid-peptide vaccines with potent anti-tumour activity.Small-Molecule Carbohydrate-Based Immunostimulants.Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination.New Directions for Natural Killer T Cells in the Immunotherapy of Cancer.Program Cell Death Receptor-1-Mediated Invariant Natural Killer T-Cell Control of Peritoneal Macrophage Modulates Survival in Neonatal Sepsis.Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy.The Influence of Invariant Natural Killer T Cells on Humoral Immunity to T-Dependent and -Independent Antigens.Safety and biodistribution of sulfated archaeal glycolipid archaeosomes as vaccine adjuvants.Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia

P2860

Q26748456-890653A0-2756-46C7-BE56-955B717E102B Q36191001-A655FE74-6DDB-4F02-96BA-4CFA6B4E50EB Q38412832-16C95581-CCA6-44E7-9E50-C86AF266C549 Q38844616-54992823-CF9B-4F95-B54D-71B0033F44A0 Q39049093-C5719CF3-960B-40B4-B79C-0C49C8D65A7D Q47094180-EFE52B88-92B9-4904-A5C0-6DE0880B13C1 Q47160878-6E0DA78B-CA42-4714-BF67-12A024502C3D Q50075685-3F14A3A6-32F4-47AC-97F0-A63FE9D9C2F9 Q50531631-F4EC8084-2802-4DD8-88E0-639D6DF33600 Q52394368-AD0CCB56-D950-4C94-ACCA-ED17589D6018 Q58799058-ACA160EF-C9B8-4218-BF20-AF0DA3F89B9E

P2860

Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination

http://www.wikidata.org/entity/Q34517948

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination

@ast

Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination

@en

Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination

@nl

type

label

Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination

@ast

Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination

@en

Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination

@nl

prefLabel

Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination

@ast

Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination

@en

Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination

@nl

P1433

Q34517948-5410271E-28AA-49DE-852A-30269E9075BF

P1476

Q34517948-0734541B-BC61-4077-BE23-3D72D352599B

P2093

Q34517948-0E9FFB9A-B99A-4852-B31C-180AC433689E

Q34517948-33D23F2D-F2AD-4553-AE16-48E5C2EB69D7

Q34517948-4D98CFEB-C415-4D8E-8878-A3F9504AE943

Q34517948-65F44C3A-6C28-40A7-9D8D-C26884EFF144

Q34517948-87E7419C-ED2B-4D70-8536-6BE7DAF8EF93

Q34517948-C589E85A-2199-4404-B8E8-395C38D4F70E

Q34517948-DF63C3DB-53A5-41D2-95CE-7AB1844E08B2

Q34517948-EB95B923-803D-45A0-8498-7338F37D9F60

Q34517948-F865D095-CF64-4D90-94EF-040CA7DE41FC

P2860

Q34517948-00A38481-FF18-409E-B4B0-1848EE08A146

Q34517948-0A195F3F-CFAE-4FA6-8674-30CBB9E845EE

Q34517948-0BF3AA34-4C4B-406E-ACBB-416BEC999C79

Q34517948-0E345C0C-1F54-4ED8-8FCB-292E5A1A0811

Q34517948-18CD8CB2-A750-4609-9C37-FFA4247FB69D

Q34517948-230D8602-A7CF-4743-9DAA-3BEEA32D7848

Q34517948-23DC7764-2E84-4FF2-A7D2-8FA5CA47AB5F

Q34517948-2FE6C089-7657-40DA-AF79-3E56AE44928B

Q34517948-38DFF770-77CB-496A-B5C6-1E3D2A35C3C7

Q34517948-4063F7D0-1AE4-4680-872A-8746E960BE7D

P304

Q34517948-7B5FB691-9DB5-46C0-AD88-183E7CA428BE

P31

Q34517948-99AAF4D6-89AB-4284-8A1F-EBD278BE9948

P356

Q34517948-10D84E81-3E5A-40F5-9AEC-6A8B11614C03

P407

Q34517948-A63D72CF-8E3A-439B-B343-1650CD1F5E98

P433

Q34517948-A7D0DA98-B5C1-4BB6-A880-DA4596471FC7

P478

Q34517948-7E10B2A0-A3DA-40C2-A6E9-A9EA856026CB

P577

Q34517948-B23B1196-7717-4720-A437-580451027E2F

P698

Q34517948-50639276-2F07-4E18-A102-2FE61994CF11

P932

Q34517948-75E8BCA4-5864-4DA6-8902-46BDAA253410

P356

J.VACCINE.2014.08.070

P1433

P1476

Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination

@en

P2093

Albert Bendelac

http://www.w3.org/2001/XMLSchema#string

Bernard Orlandini

http://www.w3.org/2001/XMLSchema#string

Haylene Nell

http://www.w3.org/2001/XMLSchema#string

Josianne Nitcheu Tefit

http://www.w3.org/2001/XMLSchema#string

Luc Teyton

http://www.w3.org/2001/XMLSchema#string

Paul B Savage

http://www.w3.org/2001/XMLSchema#string

Sandrine Crabé

http://www.w3.org/2001/XMLSchema#string

Shenglou Deng

http://www.w3.org/2001/XMLSchema#string

Vincent Serra

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic reviews of animal models: methodology versus epistemology.

Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients.

Turned on by danger: activation of CD1d-restricted invariant natural killer T cells

Fatty acid amide hydrolase shapes NKT cell responses by influencing the serum transport of lipid antigen in mice.

Glycolipid antigen induces long-term natural killer T cell anergy in mice.

PLZF induces an intravascular surveillance program mediated by long-lived LFA-1-ICAM-1 interactions.

Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals

Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia.

The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion.

Scavenger receptors target glycolipids for natural killer T cell activation.

P304

6138-6145

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2014.08.070

http://www.w3.org/2001/XMLSchema#string

P407

P433

46

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25218293

http://www.w3.org/2001/XMLSchema#string

P932

4233108

http://www.w3.org/2001/XMLSchema#string